線維腺腫の世界市場：タイプ・診断&治療・エンドユーザー・地域別の予測 (～2032年)

線維腺腫の市場規模は、2023年の7億1,000万米ドル、2024年の7億7,000万米ドルから、予測期間中は6.36％のCAGRで推移し、2032年には13億4,000万米ドルの規模に成長すると予測されています。

女性における線維腺腫の罹患率の上昇と、公教育キャンペーンを通じた線維腺腫の認知度の向上が、線維水腫市場の成長を促進する主な要因です。

線維腺腫の認知度を高めることを目的とした公教育キャンペーンは、線維腺腫市場の成長の重要な要因です。公教育キャンペーンは、線維腺腫の徴候や症状について女性に知らせるために不可欠です。このような認識の向上は、女性が定期的な乳房検査やスクリーニングを実施する動機付けとなり、積極的な健康追求行動を促進します。線維腺腫の迅速な介入と適切な管理は早期発見が条件です。さらに、一般向けの教育キャンペーンは、乳房のしこりに関する誤解を覆すのに役立ち、そのような発見にしばしば伴う不安や恐怖を軽減します。

また、線維腺腫市場の拡大は診断方法の進歩にも大きく影響されています。タイムリーで適切な医療介入に不可欠な診断ツールの進歩により、検出精度は大幅に向上しています。線維腺腫の正確な同定は不可欠です。医療専門家は、診断技術の向上により線維腺腫をより早い段階で同定することができます。タイムリーで的を絞った治療戦略を実施し、合併症の可能性を減らし、患者の転帰を改善するためには、早期同定が極めて重要です。線維腺腫の診断アプローチは、磁気共鳴画像法 (MRI) や超音波などの非侵襲的画像診断技術の導入と改良によって変容してきました。

当レポートでは、世界の線維腺腫の市場を調査し、市場の定義と概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 概要
• 促進要因
  • 公教育キャンペーンを通じた認知度の向上
  • 線維腺腫を正確に特定するための診断技術の開発・改良
  • 女性の線維腺腫の罹患率の増加
• 抑制要因
  • 線維腺腫の治療費の高額さ
• 機会
  • 線維腺腫に対する低侵襲手術や薬物療法などの新たな治療法の研究
  • 線維腺腫の治療における低侵襲手術の採用増加
• 課題
  • 線維腺腫は生命を脅かすものではない
• COVID-19の影響分析

第5章 市場要因分析

• バリューチェーン分析
• ポーターのファイブフォース分析

第6章 世界の線維腺腫市場：タイプ別

• 単純性線維腺腫
• 複雑線維腺腫

第7章 世界の線維腺腫市場：診断・治療別

• 診断
  • 超音波スキャン
  • マンモグラフィ
  • 生検
• 治療
  • クライオブレーション
  • 高強度焦点式超音波 (HIFU)
  • 乳房切除術
  • 薬剤

第8章 世界の線維腺腫市場：エンドユーザー別

• 病院・診療所
• 診断センター
• その他

第9章 世界の線維腺腫市場：地域別

• 概要
• 北米
• 欧州
• アジア太平洋
• その他の地域

第10章 競合情勢

• 競合ダッシュボード
• 市場シェア分析
• 公開企業の株式概要
• 主な展開と成長戦略

第11章 企業プロファイル

• GE HEALTHCARE
• KONINKLIJKE PHILIPS N.V.
• SHIMADZU CORPORATION
• SIEMENS HEALTHINEERS
• CANON MEDICAL SYSTEMS CORPORATION
• DILON TECHNOLOGIES
• PFIZER, INC
• ICECURE MEDICAL
• ALPINION MEDICAL SYSTEMS
• FUJIFILM HOLDINGS CORPORATION

第12章 付録

• 参考文献
• 関連レポート

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 3 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY SIMPLE FIBROADENOMA, 2019-2032 (USD MLLION)
• TABLE 4 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY COMPLEX FIBROADENOMA, 2019-2032 (USD MLLION)
• TABLE 5 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 6 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2032 (USD MLLION)
• TABLE 7 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY TREATMENT, 2019-2032 (USD MLLION)
• TABLE 8 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 9 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY HOSPITAL AND CLINICS, 2019-2032 (USD MLLION)
• TABLE 10 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSTIC CENTERS, 2019-2032 (USD MLLION)
• TABLE 11 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY OTHERS, 2019-2032 (USD MLLION)
• TABLE 12 GLOBAL FIBROADENOMA MARKET, BY REGION, 2019-2032 (USD MLLION)
• TABLE 13 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 14 NORTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 15 NORTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 16 NORTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 17 US FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 18 US FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 19 US FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 20 CANADA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 21 CANADA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 22 CANADA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 23 MEXICO FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 24 MEXICO FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 25 MEXICO FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 26 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 27 EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 28 EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 29 EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 30 GERMANY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 31 GERMANY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 32 GERMANY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 33 FRANCE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 34 FRANCE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 35 FRANCE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 36 UK FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 37 UK FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 38 UK FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 39 SPAIN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 40 SPAIN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 41 SPAIN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 42 ITALY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 43 ITALY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 44 ITALY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 45 REST OF EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 46 REST OF EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 47 REST OF EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 48 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 49 ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 50 ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 51 ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 52 CHINA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 53 CHINA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 54 CHINA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 55 INDIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 56 INDIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 57 INDIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 58 JAPAN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 59 JAPAN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 60 JAPAN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 61 SOUTH KOREA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 62 SOUTH KOREA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 63 SOUTH KOREA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 64 AUSTRALIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 65 AUSTRALIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 66 AUSTRALIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 67 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 68 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 69 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 70 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 71 REST OF THE WORLD FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 72 REST OF THE WORLD FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 73 REST OF THE WORLD FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 74 SOUTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 75 SOUTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 76 SOUTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 77 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 78 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 79 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 80 PUBLIC PLAYERS STOCK SUMMARY
• TABLE 81 PRODUCT LAUNCH
• TABLE 82 PARTNERSHIP
• TABLE 83 EXPANSION
• TABLE 84 GE HEALTHCARE: PRODUCTS OFFERED
• TABLE 85 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
• TABLE 86 SHIMADZU CORPORATION: PRODUCTS OFFERED
• TABLE 87 SHIMADZU CORPORATION: KEY DEVELOPMENTS
• TABLE 88 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
• TABLE 89 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS
• TABLE 90 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED
• TABLE 91 CANON MEDICAL SYSTEMS CORPORATION: KEY DEVELOPMENTS
• TABLE 92 DILON TECHNOLOGIES: PRODUCTS OFFERED
• TABLE 93 DILON TECHNOLOGIES: KEY DEVELOPMENTS
• TABLE 94 PFIZER, INC: PRODUCTS OFFERED
• TABLE 95 ICECURE MEDICAL: PRODUCTS OFFERED
• TABLE 96 ALPINION MEDICAL SYSTEMS: PRODUCTS OFFERED
• TABLE 97 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 GLOBAL FIBROADENOMA MARKET: STRUCTURE
• FIGURE 2 GLOBAL FIBROADENOMA MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)
• FIGURE 4 PORTER'S FIVE FORCES MODEL: GLOBAL FIBROADENOMA MARKET
• FIGURE 5 GLOBAL FIBROADENOMA MARKET, BY TYPE, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 6 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2022 (% SHARE)
• FIGURE 7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 8 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2022 (% SHARE)
• FIGURE 9 GLOBAL FIBROADENOMA MARKET, BY END-USER, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 10 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2022 (% SHARE)
• FIGURE 11 GLOBAL FIBROADENOMA MARKET, BY REGION, 2022 (% SHARE)
• FIGURE 12 NORTH AMERICA MARKET: COMPARATIVE ANALYSIS
• FIGURE 13 NORTH AMERICA MARKET: SWOT ANALYSIS
• FIGURE 14 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 15 EUROPE MARKET: COMPARATIVE ANALYSIS
• FIGURE 16 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 17 EUROPE MARKET: SWOT ANALYSIS
• FIGURE 18 ASIA PACIFIC MARKET: COMPARATIVE ANALYSIS
• FIGURE 19 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS
• FIGURE 21 REST OF THE WORLD MARKET: COMPARATIVE ANALYSIS
• FIGURE 22 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 23 REST OF THE WORLD MARKET: SWOT ANALYSIS
• FIGURE 24 COMPETITOR DASHBOARD: GLOBAL FIBROADENOMA MARKET
• FIGURE 25 GLOBAL FIBROADENOMA MARKET: COMPETITIVE ANALYSIS,
• FIGURE 26 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 27 GE HEALTHCARE: SWOT ANALYSIS
• FIGURE 28 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS
• FIGURE 29 SHIMADZU CORPORATION: SWOT ANALYSIS
• FIGURE 30 SIEMENS HEALTHINEERS: SWOT ANALYSIS
• FIGURE 31 CANON MEDICAL SYSTEMS CORPORATION: SWOT ANALYSIS
• FIGURE 32 DILON TECHNOLOGIES: SWOT ANALYSIS
• FIGURE 33 PFIZER, INC: SWOT ANALYSIS
• FIGURE 34 ICECURE MEDICAL: SWOT ANALYSIS
• FIGURE 35 ALPINION MEDICAL SYSTEMS: SWOT ANALYSIS

Global Fibroadenoma Market Research Report Information by Type (Simple Fibroadenoma and Complex Fibroadenoma), by Diagnosis & Treatment (Diagnosis [Ultrasound Scan, Mammography, and Biopsy] and Treatment [Cryoablation, High Intensity Focused Ultrasound (HIFU), Lumpectomy, and Drugs {Dydrogesterone, Medroxyprogesterone, Selective Estrogen Receptor Modulators, and Others}], by End User (Hospital and Clinics, Diagnostic Centers, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market overview

In 2023, the fibroadenoma market was estimated to be worth USD 0.71 billion. During the forecast period (2024-2032), the Fibroadenoma Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.36%, increasing from USD 0.77 billion in 2024 to USD 1.34 billion by 2032.

Rising incidences of fibroadenoma among women and increased awareness of fibroadenoma through public education campaigns are the primary factors propelling the growth of the fibroedema market.

Public education campaigns that aim to raise awareness of fibroadenoma are a significant factor in the growth of the fibroadenoma market. Public education campaigns are essential for informing women about the signs and symptoms of fibroadenoma. This increased awareness motivates women to undertake routine breast examinations and screenings and promotes proactive health-seeking behavior. The expeditious intervention and appropriate management of fibroadenomas are contingent upon early detection. Additionally, public education campaigns assist in the debunking of myths and misconceptions regarding breast lumps, thereby reducing the anxiety and dread that are often associated with such discoveries.

Additionally, the expansion of the fibroadenoma market is significantly influenced by the advancement of diagnostic methods. The precision of detection has been substantially improved by advancements in diagnostic tools, which are essential for timely and appropriate medical intervention. Accurate identification of fibroadenomas is essential. Healthcare professionals can identify fibroadenomas at an earlier stage with the assistance of improved diagnostic techniques. There is a critical need for early identification in order to implement treatment strategies that are timely and targeted, reduce the likelihood of complications, and improve patient outcomes. The diagnostic approach to fibroadenomas has been transformed by the introduction and refinement of non-invasive imaging technologies, including magnetic resonance imaging (MRI) and ultrasound.

Market segment insights

The Fibroadenoma Market is segmented into simple and complex fibroadenoma based on type.

The fibroadenoma market is segmented into 2 categories: diagnosis and treatment.

The fibroadenoma market is segmented into hospitals & clinics, ambulatory surgical centers, and others based on the end user.

Regional Perspectives

In 2022, North America held the largest market share of over 38.49% due to the advanced diagnostic techniques, medical infrastructure, and reimbursement policies and insurance coverage. Additionally, North Americans are more cognizant of health concerns and have greater access to healthcare than other regions. Even in cases where fibroadenomas are asymptomatic, this results in more frequent exams and diagnoses.

The fibroadenoma market in Europe is expected to experience substantial growth during the forecast year, 2024-2032, because of the growing emphasis on minimally invasive procedures for fibroadenomas, such as cryoablation and vacuum-assisted excision, which are particularly prevalent in Europe. The region's hospitals and institutions are well-equipped to perform these procedures, which attract patients who are interested in less invasive alternatives.

The Asia-Pacific fibroadenoma market is the fastest-growing region during the forecast period because of the frequent introduction of breast diagnosis and treatment devices through expansion. IceCure Medical Ltd. announced in May 2023 that ProSense had been installed and inaugurated at Kovai Medical Center and Hospital ("KMCH") in India.

Major Players

GE Healthcare (US), Koninklijke Philips N.V. (Germany), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Canon Medical Systems Corporation (Japan), Dilon Technologies (US), Pfizer, Inc. (US), IceCure Medical (Israel), Alpinion Medical Systems (South Korea), and Fujifilm Holdings Corporation (Japan) are among the key companies in the fibroadenoma market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASED AWARENESS ABOUT FIBROADENOMA THROUGH PUBLIC EDUCATION CAMPAIGNS
  • 4.2.2 DEVELOPMENT OF IMPROVED DIAGNOSTIC TECHNIQUES TO ACCURATELY IDENTIFY FIBROADENOMA
  • 4.2.3 INCREASING PREVALENCE OF FIBROADENOMA AMONG WOMEN
• 4.3 RESTRAINTS
  • 4.3.1 HIGH COST OF TREATMENT OF FIBROADENOMA
• 4.4 OPPORTUNITY
  • 4.4.1 RESEARCH INTO NEW TREATMENT OPTIONS FOR FIBROADENOMA, SUCH AS MINIMALLY INVASIVE SURGICAL PROCEDURES OR MEDICATIONS
  • 4.4.2 GROWING ADOPTION OF MINIMALLY INVASIVE SURGICAL PROCEDURES FOR THE TREATMENT OF FIBROADENOMA
• 4.5 CHALLENGES
  • 4.5.1 NON-LIFE THREATENING NATURE OF FIBROADENOMAS
• 4.6 IMPACT ANALYSIS OF COVID-19
  • 4.6.1 IMPACT 0N OVERALL FIBROADENOMA INDUSTRY
    • 4.6.1.1 ECONOMIC IMPACT
  • 4.6.2 IMPACT ON GLOBAL FIBROADENOMA MARKET
  • 4.6.3 IMPACT ON THE SUPPLY CHAIN OF FIBROADENOMA
  • 4.6.4 IMPACT ON MARKET DEMAND OF FIBROADENOMA
    • 4.6.4.1 IMPACT DUE TO RESTRICTIONS/LOCKDOWN
    • 4.6.4.2 CONSUMER SENTIMENTS
  • 4.6.5 IMPACT ON PRICING OF FIBROADENOMA

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 RAW MATERIALS
  • 5.1.2 MANUFACTURING / PRODUCTION/ PROCESSING
  • 5.1.3 DISTRIBUTION CHANNEL
  • 5.1.4 END-USER
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 BARGAINING POWER OF SUPPLIERS
  • 5.2.2 BARGAINING POWER OF BUYERS
  • 5.2.3 THREAT OF NEW ENTRANTS
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL FIBROADENOMA MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 SIMPLE FIBROADENOMA
• 6.3 COMPLEX FIBROADENOMA

7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT

• 7.1 INTRODUCTION
• 7.2 DIAGNOSIS
  • 7.2.1 ULTRASOUND SCAN
  • 7.2.2 MAMMOGRAPHY
  • 7.2.3 BIOPSY
• 7.3 TREATMENT
  • 7.3.1 CRYOBLATION
  • 7.3.2 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)
  • 7.3.3 LUMPECTOMY
  • 7.3.4 DRUGS
    • 7.3.4.1 DYDROGESTERONE
    • 7.3.4.2 MEDROXYPROGESTERONE
    • 7.3.4.3 SELECTIVE ESTROGEN RECEPTOR MODULATORS
    • 7.3.4.4 OTHERS

8 GLOBAL FIBROADENOMA MARKET, BY END-USER

• 8.1 INTRODUCTION
• 8.2 HOSPITAL AND CLINICS
• 8.3 DIAGNOSTIC CENTERS
• 8.4 OTHERS

9 GLOBAL FIBROADENOMA MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
  • 9.2.3 MEXICO
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 SPAIN
  • 9.3.5 ITALY
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 SOUTH AMERICA
  • 9.5.2 MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 COMPETITION DASHBOARD
• 10.3 MARKET SHARE ANALYSIS,
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.5.1 PRODUCT LAUNCH
  • 10.5.2 PARTNERSHIP
  • 10.5.3 EXPANSION

11 COMPANY PROFILES

• 11.1 GE HEALTHCARE
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGY
• 11.2 KONINKLIJKE PHILIPS N.V.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGY
• 11.3 SHIMADZU CORPORATION
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGY
• 11.4 SIEMENS HEALTHINEERS
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGY
• 11.5 CANON MEDICAL SYSTEMS CORPORATION
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 SWOT ANALYSIS
  • 11.5.5 KEY DEVELOPMENTS
  • 11.5.6 KEY STRATEGY
• 11.6 DILON TECHNOLOGIES
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 PRODUCTS OFFERED
  • 11.6.3 SWOT ANALYSIS
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGY
• 11.7 PFIZER, INC
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGY
• 11.8 ICECURE MEDICAL
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGY
• 11.9 ALPINION MEDICAL SYSTEMS
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 PRODUCTS OFFERED
  • 11.9.3 KEY DEVELOPMENTS
  • 11.9.4 SWOT ANALYSIS
  • 11.9.5 KEY STRATEGY
• 11.10 FUJIFILM HOLDINGS CORPORATION
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 PRODUCTS OFFERED
  • 11.10.3 KEY DEVELOPMENTS
  • 11.10.4 SWOT ANALYSIS
  • 11.10.5 KEY STRATEGY

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS